Featuring interviews with Drs Beth Y Karlan, Maurie Markman, Richard T Penson and Angeles Alvarez Secord. (Audio Content)
OVERVIEW OF ACTIVITY
Management of ovarian cancer (OC) includes optimal surgical debulking followed by postoperative chemotherapy and, in most cases, subsequent medical management when the disease recurs. Although many single-agent and combination chemotherapy regimens have been studied, only recently have antibody and small-molecule growth-inhibitory targeted agents been integrated into the OC research milieu. It is hoped that the results from these trials will lead to the emergence of new therapeutic agents and changes or enhancements in the indications for existing treatment strategies, ultimately improving the duration and quality of life for patients with metastatic OC. To bridge the gap between research and patient care, this issue of Ovarian Cancer Update features one-on-one discussions with leading gynecologic oncology investigators. By providing information on the latest research developments, this activity attempts to assist medical and gynecologic oncologists with the formulation of therapeutic strategies, which in turn facilitates optimal patient care.
LEARNING OBJECTIVES
Featuring interviews with Drs Beth Y Karlan, Maurie Markman, Richard T Penson and Angeles Alvarez Secord. (Audio Content)